Refining the definition of HER2‐low class in invasive breast cancer

BACKGROUND: Emerging evidence indicates that breast cancer (BC) patients whose tumours express HER2 protein without HER2 gene amplification (HER2‐low), can benefit from antibody–drug conjugates (ADC). However, the current definition of HER2‐low BC remains incomplete with low rates of concordance. Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Atallah, Nehal M, Toss, Michael S, Green, Andrew R, Mongan, Nigel P, Ball, Graham, Rakha, Emad A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826019/
https://www.ncbi.nlm.nih.gov/pubmed/36030496
http://dx.doi.org/10.1111/his.14780

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9826019/
https://www.ncbi.nlm.nih.gov/pubmed/36030496
http://dx.doi.org/10.1111/his.14780

Ejemplares similares